![](/images/graphics-bg.png)
The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
Joint Authors
Koren, Gideon
Moretti, Myla E.
Caprara, Daniela
Drehuta, Irina
Yeung, Emily
Cheung, Stefanie
Federico, Lisa
Source
Obstetrics and Gynecology International
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-12-13
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known to cause fetal renal damage in pregnancy.
Due to conflicting reports in the literature, their safety after first trimester exposure has been debated.
Our aim was to determine whether the use of ACE inhibitors or ARBs in the first trimester of pregnancy is associated with an increased risk for major malformations or other adverse outcomes.
All subjects were prospectively enrolled from among women contacting a teratogen information service.
At initial contact, details of maternal medical history and exposures were collected and follow-up interviews were conducted to ascertain pregnancy outcomes.
Two comparator groups, women with hypertension treated with other antihypertensives, and healthy controls were also recruited.
Baseline maternal characteristics were not different among the three groups.
There were no differences in rates of major malformations.
Both the ACE-ARBs and disease-matched groups exhibited significantly lower birth weight and gestational ages than the healthy controls (P<0.001 for both variables).
There was a significantly higher rate of miscarriage noted in the ACE/ARB group (P<0.001).
These results suggest that ACE inhibitors/ARBs are not major human teratogens; however, they may be associated with an increased risk for miscarriage.
American Psychological Association (APA)
Moretti, Myla E.& Caprara, Daniela& Drehuta, Irina& Yeung, Emily& Cheung, Stefanie& Federico, Lisa…[et al.]. 2011. The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Obstetrics and Gynecology International،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-1029968
Modern Language Association (MLA)
Moretti, Myla E.…[et al.]. The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Obstetrics and Gynecology International No. 2012 (Dec. 2012), pp.1-6.
https://search.emarefa.net/detail/BIM-1029968
American Medical Association (AMA)
Moretti, Myla E.& Caprara, Daniela& Drehuta, Irina& Yeung, Emily& Cheung, Stefanie& Federico, Lisa…[et al.]. The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Obstetrics and Gynecology International. 2011. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-1029968
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1029968